☆ 4.6 Article

TP53/KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma

FRONTIERS IN GENETICS (2022)

Related references

Note: Only part of the references are listed.

Article Surgery

The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer

Catherine G. Tran et al.

Summary: Laterality, KRAS mutation, and microsatellite instability status were not independent prognostic factors in patients with stage I-III colon cancer after curative resection. However, the effect of laterality was opposite based on KRAS status, with left-sided tumors associated with worse overall survival in mutated KRAS patients and better overall survival in wild-type KRAS individuals.

SURGERY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma

Shao-Lai Zhou et al.

Summary: This study characterized the genomic evolution during ICC relapse and identified SLIT2 as a driver of tumor dissemination and tumor-associated neutrophil infiltration.

HEPATOLOGY (2022)

Add to Collection

Article Oncology

PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma

Wenbo Zou et al.

Summary: This study identified PIWIL4 and SUPT5H as pivotal biomarkers for predicting the prognosis of patients with intrahepatic cholangiocarcinoma. A prognostic signature was developed that effectively distinguished patients in high- and low-risk groups. The biomarkers were also found to be correlated with the tumor microenvironment, suggesting their potential value in prognostic prediction.

CANCER CELL INTERNATIONAL (2021)

Add to Collection

Article Oncology

TP53 alterations of hormone-naive prostate cancer in the Chinese population

Zhengfang Liu et al.

Summary: The study found that TP53 alterations were more frequent in Chinese HNPC samples and correlated with alterations in the Wnt signaling pathway, while CDH1 alterations were associated with rapid biochemical recurrence (BCR). TP53 status was at the core of the genomic alteration landscape in Chinese HNPC with strong connections to other signaling pathways, and the mutually exclusive relationship between TP53 and Wnt/CTNNB1 further molecularly characterized subsets of prostate cancers.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

Add to Collection

Article Cell Biology

TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer

Zaoqu Liu et al.

Summary: A recent study revealed that CRC patients with TTN/OBSCN 'Double-Hit' phenotype had significantly better prognosis, an 'immune-hot' subtype, and potentially better immunotherapeutic efficacy.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)

Add to Collection

Article Oncology

KRAS(G12C)/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (>= 50%) lung adenocarcinoma

Nikolaj Frost et al.

Summary: This study identified KRAS and TP53-defined mutational subgroups in PD-L1 high non-small cell lung cancer patients, revealing that patients with KRAS(G12C)/TP53 co-mutations showed long-term response while those with KRAS(other)/TP53 mutations had poor prognosis.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes

Xiaofeng Chen et al.

Summary: This study found that KRAS and TP53 mutations are more frequent in advanced BTC, with KRAS-TP53 co-mutations associated with a favorable response to immunotherapy. Compared to GBC, CHOL has more mutations in genes involved in KRAS signaling, potentially leading to inferior immunotherapy outcomes. Additionally, a genomic signature including 11 genes was developed to predict prognosis and immunotherapy outcomes in CHOL and GBC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Cell Biology

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

Di Shi et al.

Summary: p53, an evolutionarily conserved tumor suppressor, plays a central role in response to cellular stresses and regulates various biological processes. In addition to well-known functions, p53 also modulates innate and adaptive immune responses, impacting tumor progression. Understanding the role of p53 in immunity regulation is crucial for developing effective anti-tumor immunotherapies for patients with TP53 mutations or depletion.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Genetics & Heredity

Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma

Zaoqu Liu et al.

Summary: The study identified RYR2 gene mutation as a potential biomarker for prognosis, TMB, and immunotherapy of EAC patients, suggesting that patients with RYR2 mutation might benefit more from immunotherapy. Multiple bioinformatics algorithms demonstrated that RYR2 mutation could enhance antitumor immunity and upregulated signaling pathways related to immune response in EAC.

FRONTIERS IN GENETICS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma

Guo-Feng Zhang et al.

BIOSCIENCE REPORTS (2020)

Add to Collection

Review Gastroenterology & Hepatology

Systemic therapies for intrahepatic cholangiocarcinoma

Robin Kate Kelley et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Molecular targeted therapies: Ready for prime time in biliary tract cancer

Angela Lamarca et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Cell Biology

High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer

Akio Tsutaho et al.

CELL COMMUNICATION AND SIGNALING (2020)

Add to Collection

Article Oncology

Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease

Alexandre Sauriol et al.

CANCERS (2020)

Add to Collection

Review Gastroenterology & Hepatology

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances

Alphonse E. Sirica et al.

HEPATOLOGY (2019)

Add to Collection

Review Oncology

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Rachel Grosser et al.

CANCER CELL (2019)

Add to Collection

Article Oncology

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer

Erin Bange et al.

JCO PRECISION ONCOLOGY (2019)

Add to Collection

Review Oncology

Implementing TMB measurement in clinical practice: considerations on assay requirements

Reinhard Buettner et al.

ESMO OPEN (2019)

Add to Collection

Review Oncology

Cholangiocarcinoma - evolving concepts and therapeutic strategies

Sumera Rizvi et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014

Samuel O. Antwi et al.

ANNALS OF HEPATOLOGY (2018)

Add to Collection

Article Pathology

Cancer related gene alterations can be detected with next-generation sequencing analysis of bile in diffusely infiltrating type cholangiocarcinoma

Chang Hun Lee et al.

EXPERIMENTAL AND MOLECULAR PATHOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

Mutational landscape of intrahepatic cholangiocarcinoma

Shanshan Zou et al.

NATURE COMMUNICATIONS (2014)

Add to Collection

Article Gastroenterology & Hepatology

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

A Tannapfel et al.

GUT (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.